Haematological cancer: Lenalidomide maintenance-perils of a premature denouement

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Of three randomized trials testing lenalidomide maintenance in myeloma, a survival benefit is apparent in one. An increased risk of second cancers is seen in all three trials. Maintenance must be considered after a review of risks and benefits, but it is premature to recommend lenalidomide maintenance for all patients.

Original languageEnglish (US)
Pages (from-to)372-374
Number of pages3
JournalNature Reviews Clinical Oncology
Volume9
Issue number7
DOIs
StatePublished - Jul 1 2012

    Fingerprint

ASJC Scopus subject areas

  • Oncology

Cite this